DOXORUBICIN 2 MG/ML SOLUTION FOR INFUSION 2 mg/ml Concentrate for solution for infusion 5ml Vial

Product Overview

Doxorubicin 2 mg/ml Solution for Infusion is an essential chemotherapy medication used in the treatment of a wide range of cancers.

This concentrate for solution for infusion is provided in a 5ml vial, formulated for intravenous administration by healthcare professionals.

As an anthracycline cytotoxic agent, Doxorubicin works by interfering with the genetic material of cancer cells, thereby inhibiting their growth and division.

Key Benefits

Doxorubicin is a critical component in various cancer treatment regimens, offering significant therapeutic advantages:

• Effective in treating a broad spectrum of solid tumors and hematological malignancies, including breast cancer, ovarian cancer, bladder cancer, small cell lung cancer, lymphomas, and leukemias.
• Plays a vital role in polychemotherapy regimens, often used in combination with other anti-cancer agents to achieve better outcomes.
• Administered intravenously, allowing for precise dosing and rapid systemic distribution to target cancer cells throughout the body.

How to Use

Doxorubicin 2 mg/ml Solution for Infusion must only be administered by qualified healthcare professionals experienced in the use of cytotoxic agents.

1. The concentrate is diluted prior to intravenous administration.
2. Administered via slow intravenous infusion, typically over 3 to 5 minutes, into a free-flowing intravenous infusion.
3. The dosage and administration schedule are highly individualized, determined by the patient's specific cancer type, stage, overall health, and response to treatment.
4. Close monitoring for adverse reactions, particularly cardiac function and blood counts, is essential during and after treatment.

Caution & Warnings

• Cardiotoxicity: Doxorubicin can cause severe, cumulative, and potentially irreversible myocardial damage leading to congestive heart failure. Regular monitoring of cardiac function is mandatory.
• Myelosuppression: Bone marrow suppression, resulting in leukopenia, neutropenia, thrombocytopenia, and anemia, is a dose-limiting toxicity. Complete blood counts must be performed before and during each cycle of therapy.
• Extravasation: Avoid extravasation as it can lead to severe local tissue necrosis. If extravasation occurs, discontinue the infusion immediately and apply local measures.
• Secondary Malignancies: Treatment with Doxorubicin may increase the risk of developing secondary acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
• Contraindications: Do not use in patients with severe myocardial insufficiency, recent myocardial infarction, severe persistent myelosuppression, or known hypersensitivity to Doxorubicin, other anthracyclines, or anthracenediones.
• Pregnancy and Breastfeeding: Doxorubicin is embryotoxic and teratogenic. It is contraindicated during pregnancy and breastfeeding.
• Hepatic Impairment: Dose reduction is required in patients with impaired liver function.

Ingredients

• Active Ingredient: Doxorubicin hydrochloride 2 mg/ml
• Excipients: Sodium Chloride, Water for Injections.

Product Details

• Form: Concentrate for solution for infusion
• Strength: 2 mg/ml
• Volume: 5 ml per vial
• Packaging: Single-use glass vial
• Manufacturer: Hospira (a Pfizer company)
• Legal Status: Prescription Only Medicine (POM)